Mumbai, May 13 -- Profit before tax was at Rs 369.12 crore in the March 2026 quarter, up 4% from Rs 354.9 crore recorded in corresponding quarter last year.

Total expenses marginally rose 0.78% to Rs 655.75 crore in Q4 FY26 over Q4 FY25. Cost of materials consumed was at Rs 101.47 crore (down 6.34% YoY) while employee benefits expense stood at Rs 164.75 crore (up 7.70% YoY) during the period under review.

EBITDA stood at Rs 347 crore in the quarter, up 5% year-on-year. EBITDA margin improved by 90 basis points to 35.1%.

The General Medicines portfolio delivered a competitive performance during the quarter, with the top four promoted brands outperforming the market, according to IQVIA data. Key brands including Augmentin, Calpol and T-B...